2. Academic Validation
  3. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19

Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19

  • Environ Res. 2020 Sep;188:109858. doi: 10.1016/j.envres.2020.109858.
Athina Angelopoulou 1,  Nikos Alexandris 1,  Evangelia Konstantinou 1,  Konstantinos Mesiakaris 1,  Charilaos Zanidis 1,  Konstantinos Farsalinos 1,  Konstantinos Poulas 2
Affiliations

Affiliations

  • 1 Laboratory of Molecular Biology and Immunology, Department of Pharmacy, University of Patras, 26500, Greece.
  • 2 Laboratory of Molecular Biology and Immunology, Department of Pharmacy, University of Patras, 26500, Greece. Electronic address: [email protected].
PMID: 32846644 DOI: 10.1016/j.envres.2020.109858
Abstract

According to numerous recent publications, the COVID-19 patients have lymphopenia, higher infection-related biomarkers and several elevated inflammatory cytokines (i.e. tumor necrosis factor (TNF)-α, interleukin IL-2R and IL-6). The total number of B cells, T cells and NK cells are significantly decreased. RNA viruses, SARS-CoV-2 included, hit the innate immune system in order to cause Infection, through TLRs 3, 7 and 8. Imiquimod is an immune-stimulator that activates TLR 7 and can be used to enhance the innate and adaptive immunity. Preclinical and clinical trials are proposed.

Keywords

Covid-19; Imiquimod; Treatment.

Figures
Products